NCT02963727

Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis

Knee Osteoarthrosis (KOA) in Jordanian Patients: a Phase I Dose-finding Study Using Wharton Jelly Derived Mesenchymal Stem Cells (WJMSC) for Advanced Stage III and IV KOA

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Hanan Jafar · Academic / Other
• Sex: All
• Age: 42 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Detailed description

Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to strict inclusion and exclusion criteria. These patients will be injected with Wharton Jelly derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.

Conditions

• Knee Osteoarthrosis

Interventions

Type	Name	Description
BIOLOGICAL	Wharton Jelly derived mesenchymal stem cell	Intra-articular Wharton Jelly derived mesenchymal stem cell injection.

Timeline

• Start date: 2017-01-27
• Primary completion: 2021-10-01
• Completion: 2021-12-01
• First posted: 2016-11-15
• Last updated: 2021-04-28

Locations

1 site across 1 country: Jordan